Drug intelligence / Profile preview

zhiley capsule

Development stage: Unknown
Lead developer: Zhejiang Shiqiang Pharmaceutical
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Zhiley Capsule is a Traditional Chinese Medicine (TCM) candidate developed by Zhejiang Shiqiang Pharmaceutical for the treatment of major depressive disorder (MDD). It is specifically formulated to address the TCM pattern of qi-yin deficiency with liver depression transforming into heat. The drug is currently being evaluated in a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial in China (CTR20244526) to assess its efficacy and safety over an 8-week treatment period in adults with MDD without psychotic features.

Brand names: Zhiley Capsule
Other names: Zhiley

Beyond the preview

Go deeper on zhiley capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zhiley capsule.

Explore the full profile